Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Don’t miss cardiovascular risk factors in transgender patients

Publish date:: November 13, 2020

Key clinical point: Transgender individuals may have elevated cardiovascular risk.

Major finding: The incidence of undiagnosed hypertension and hyperlipidemia was 6.8% and 11.3%, respectively, in transgender individuals who had not yet undergone gender-affirming hormone therapy.

Study details: The data come from a retrospective study of 427 transgender persons seeking gender-affirming hormone therapy.

Disclosures: The study received no outside funding. Lead author Dr. Denby had no financial conflicts to disclose.

Citation:

Denby KJ et al. AHA 2020, Presentation P2274.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,